174 related articles for article (PubMed ID: 7026076)
1. Acivicin. An antitumor antibiotic.
Poster DS; Bruno S; Penta J; Neil GL; McGovren JP
Cancer Clin Trials; 1981; 4(3):327-30. PubMed ID: 7026076
[TBL] [Abstract][Full Text] [Related]
2. Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125.
Houchens DP; Ovejera AA; Sheridan MA; Johnson RK; Bogden AE; Neil GL
Cancer Treat Rep; 1979 Mar; 63(3):473-6. PubMed ID: 427827
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Jayaram HN; Ardalan B; Deas M; Johnson RK
Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).
Neil GL; Berger AE; McPartland RP; Grindey GB; Bloch A
Cancer Res; 1979 Mar; 39(3):852-6. PubMed ID: 427775
[No Abstract] [Full Text] [Related]
5. Sex- and age-related mouse toxicity and disposition of the amino acid antitumor agent, acivicin.
McGovren JP; Neil GL; Chan PJ; Stewart JC
J Pharmacol Exp Ther; 1981 Mar; 216(3):433-40. PubMed ID: 7205622
[TBL] [Abstract][Full Text] [Related]
6. Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture.
Williams MG; Earhart RH; Bailey H; McGovren JP
Cancer Res; 1990 Sep; 50(17):5475-80. PubMed ID: 2386952
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.
Rosenfeld H; Roberts J
Cancer Res; 1981 Apr; 41(4):1324-8. PubMed ID: 7214322
[TBL] [Abstract][Full Text] [Related]
8. Animal behavioral and neurochemical effects of the CNS toxic amino acid antitumor agent, acivicin.
McGovren JP; Williams MG; Tang AH; VonVoigtlander PF; Piercey MF; Einspahr FJ; Schreur PJ
Res Commun Chem Pathol Pharmacol; 1989 Feb; 63(2):215-29. PubMed ID: 2711026
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of gamma-glutamyl transpeptidase from human pancreatic carcinoma cells by (alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501).
Allen L; Meck R; Yunis A
Res Commun Chem Pathol Pharmacol; 1980 Jan; 27(1):175-82. PubMed ID: 6102405
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cell cycle progression of human pancreatic carcinoma cells in vitro by L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, Acivicin (NSC 163501).
Meck RA; Clubb KJ; Allen LM; Yunis AA
Cancer Res; 1981 Nov; 41(11 Pt 1):4547-53. PubMed ID: 7306976
[TBL] [Abstract][Full Text] [Related]
11. L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine.
Jayaram HN; Cooney DA; Ryan JA; Neil G; Dion RL; Bono VH
Cancer Chemother Rep; 1975; 59(3):481-91. PubMed ID: 1147
[TBL] [Abstract][Full Text] [Related]
12. Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).
Neil GL; Berger AE; Bhuyan BK; Blowers CL; Kuentzel SL
Adv Enzyme Regul; 1978; 17():375-98. PubMed ID: 757314
[No Abstract] [Full Text] [Related]
13. Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase.
Holcenberg JS
Cancer Treat Rep; 1979 Jun; 63(6):1109-14. PubMed ID: 466650
[TBL] [Abstract][Full Text] [Related]
14. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study.
Maroun JA; Fields AL; Pater JL; Stewart DJ; Cripps C; Eisenhauer E
Cancer Treat Rep; 1984 Sep; 68(9):1121-3. PubMed ID: 6478451
[TBL] [Abstract][Full Text] [Related]
16. In vivo inactivation by acivicin of carbamoyl-phosphate synthetase II in rat hepatoma.
Aoki T; Sebolt J; Weber G
Biochem Pharmacol; 1982 Mar; 31(6):927-32. PubMed ID: 7082374
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials.
McGovren JP; Pratt EA; Belt RJ; Taylor SA; Benjamin RS; Ardalan B; Ohnuma T
Cancer Res; 1985 Sep; 45(9):4460-3. PubMed ID: 3896481
[TBL] [Abstract][Full Text] [Related]
18. Biochemical pharmacology of acivicin in rat hepatoma cells.
Lui MS; Kizaki H; Weber G
Biochem Pharmacol; 1982 Nov; 31(21):3469-73. PubMed ID: 7150366
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacological study of acivicin by 24-hour continuous infusion.
Weiss GR; McGovren JP; Schade D; Kufe DW
Cancer Res; 1982 Sep; 42(9):3892-5. PubMed ID: 7105049
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
